Wanbury valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
10.89×————
4.21×————
0.93×————
Enterprise multiples
1.26×————
8.34×————
9.81×————
Yield
9.2%————
−4.5%————
Reference — adjusted share basis
₹174.16————
₹16.00₹18.93₹8.74₹8.70−₹2.98
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

WANBURY₹174.16

Wanbury Limited

· Pharma & Health
₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹609 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————10.89
P/B————4.21
P/Sales————0.93
Enterprise Multiples
EV/Sales————1.26
EV/EBITDA————8.34
EV/EBIT————9.81
Yield
Earnings Yield %————9.18
FCF Yield %————-4.52
Reference — adjusted share basis
Price (FY-end close, adj.)————174.16
EPS (adj.)-2.988.708.7418.9316.00
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.